MiNA Therapeutics Collaborates with Nippon Shinyaku on RNAa Therapeutics for Rare Neurodegenerative Diseases
Shots:
- MiNA & Nippon Shinyaku have entered into a research collaboration & licensing agreement under which MiNA will identify RNAa candidates by employing its RNAa algorithm and technology platform as a treatment of rare neurodegenerative disorders
- Nippon Shinyaku gains an option to exclusively license the therapeutic candidates supported by the early-stage preclinical data to further carry out their research, development & commercialization activities
- MiNA will receive an undisclosed upfront payment and development milestones for the RNAa candidates. If Nippon Shinyaku exercises its exclusive option, it will get the payment for development and commercialization, milestones plus sales-based royalties post-product launch
Ref: MiNA Therapeutics | Image: MiNA Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
